Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 8/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470163 | 0.87 | KCNN4 (0.43) | KCNN4PDE2AAAK1SSTR4RORC | |
| SCHEMBL22470517 | 0.86 | KCNN4 (0.56) | KCNN4PDE2ACTSD | |
| SCHEMBL29356882 | 0.86 | KCNN4 (0.48) | KCNN4PDE2AAAK1DRD2 | |
| SCHEMBL28655611 | 0.81 | KCNN4 (0.53) | KCNN4PDE2ACTSD | |
| SCHEMBL22470493 | 0.80 | HDAC3 (0.41) | CTSDSSTR4 | |
| SCHEMBL22470506 | 0.80 | MAPT (0.47) | SSTR4DRD2MAPT | |
| SCHEMBL22470120 | 0.79 | MAPT (0.39) | AAK1SSTR4DRD2MAPT | |
| SCHEMBL22470484 | 0.77 | KCNN4 (0.45) | KCNN4PDE2ARORC | |
| SCHEMBL22470486 | 0.76 | KCNN4 (0.61) | KCNN4PDE2AAAK1DRD2 | |
| SCHEMBL22470384 | 0.75 | KCNN4 (0.50) | KCNN4PDE2ACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020193419-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885PDE2A 730/4885AAK1 676/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885PDE2A 999/4885AAK1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.